DE-Tübingen-MEDUNITUEBINGEN
Welcome,         Profile    Billing    Logout  
 3 Trials 
11 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Christopeit, Maximilian
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
06/27
06/27
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
NCT04628026: Phase III Study of Induction and Consolidation Chemotherapy with Venetoclax in Patients with Newly Diagnosed AML or MDS-EB-2

Active, not recruiting
3
650
Europe
Venetoclax, Placebo, Standard chemotherapy, Autologous stem cell transplantation, Allogeneic stem cell transplantation
University of Ulm, Stichting Hemato-Oncologie voor Volwassenen Nederland
Acute Myeloid Leukemia, Myelodysplastic Syndromes
03/29
02/32
LENNON, NCT05384691: Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions

Recruiting
2
213
Europe
Luspatercept Injection, LUS
University of Leipzig, Celgene Corporation
Myelodysplastic Syndromes, Anemia
07/26
07/27
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project

Recruiting
N/A
50000
Europe
University of Ulm
Acute Myeloid Leukemia (AML), MDS/AML
12/44
12/44
Lengerke, Claudia
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
06/27
06/27
NCT04628026: Phase III Study of Induction and Consolidation Chemotherapy with Venetoclax in Patients with Newly Diagnosed AML or MDS-EB-2

Active, not recruiting
3
650
Europe
Venetoclax, Placebo, Standard chemotherapy, Autologous stem cell transplantation, Allogeneic stem cell transplantation
University of Ulm, Stichting Hemato-Oncologie voor Volwassenen Nederland
Acute Myeloid Leukemia, Myelodysplastic Syndromes
03/29
02/32
NCT06652438: Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Recruiting
3
415
Europe
Revumenib, Placebo
Stichting Hemato-Oncologie voor Volwassenen Nederland, German-Austrian Acute Myeloid Leukemia Study Group, United Kingdom AML Research Network
Acute Myeloid Leukemia, Adult
12/29
07/31
VenSwitch, NCT06156579: Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML

Recruiting
2
27
Europe
Decitabine, Dacogen, Venetoclax, Venclyxto, Venclexta
University Hospital Tuebingen
AML, MDS
09/26
03/27
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project

Recruiting
N/A
50000
Europe
University of Ulm
Acute Myeloid Leukemia (AML), MDS/AML
12/44
12/44
SYS01, NCT05787964: Immunity to Infection in Healthy Participants and Participants With Cancer

Active, not recruiting
N/A
200
Europe
Biological sample collection
University Hospital Tuebingen
Influenza, SARS-CoV-2, Hematologic Malignancy, Solid Tumor
09/24
09/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Christopeit, Maximilian
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
06/27
06/27
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
NCT04628026: Phase III Study of Induction and Consolidation Chemotherapy with Venetoclax in Patients with Newly Diagnosed AML or MDS-EB-2

Active, not recruiting
3
650
Europe
Venetoclax, Placebo, Standard chemotherapy, Autologous stem cell transplantation, Allogeneic stem cell transplantation
University of Ulm, Stichting Hemato-Oncologie voor Volwassenen Nederland
Acute Myeloid Leukemia, Myelodysplastic Syndromes
03/29
02/32
LENNON, NCT05384691: Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions

Recruiting
2
213
Europe
Luspatercept Injection, LUS
University of Leipzig, Celgene Corporation
Myelodysplastic Syndromes, Anemia
07/26
07/27
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project

Recruiting
N/A
50000
Europe
University of Ulm
Acute Myeloid Leukemia (AML), MDS/AML
12/44
12/44
Lengerke, Claudia
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
06/27
06/27
NCT04628026: Phase III Study of Induction and Consolidation Chemotherapy with Venetoclax in Patients with Newly Diagnosed AML or MDS-EB-2

Active, not recruiting
3
650
Europe
Venetoclax, Placebo, Standard chemotherapy, Autologous stem cell transplantation, Allogeneic stem cell transplantation
University of Ulm, Stichting Hemato-Oncologie voor Volwassenen Nederland
Acute Myeloid Leukemia, Myelodysplastic Syndromes
03/29
02/32
NCT06652438: Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Recruiting
3
415
Europe
Revumenib, Placebo
Stichting Hemato-Oncologie voor Volwassenen Nederland, German-Austrian Acute Myeloid Leukemia Study Group, United Kingdom AML Research Network
Acute Myeloid Leukemia, Adult
12/29
07/31
VenSwitch, NCT06156579: Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML

Recruiting
2
27
Europe
Decitabine, Dacogen, Venetoclax, Venclyxto, Venclexta
University Hospital Tuebingen
AML, MDS
09/26
03/27
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project

Recruiting
N/A
50000
Europe
University of Ulm
Acute Myeloid Leukemia (AML), MDS/AML
12/44
12/44
SYS01, NCT05787964: Immunity to Infection in Healthy Participants and Participants With Cancer

Active, not recruiting
N/A
200
Europe
Biological sample collection
University Hospital Tuebingen
Influenza, SARS-CoV-2, Hematologic Malignancy, Solid Tumor
09/24
09/24

Download Options